Regulus sets $10-12 price range for $55m IPO
This article was originally published in Scrip
Executive Summary
Regulus Therapeutics said in a filing with the US Securities and Exchange Commission (SEC) on 7 September that it will price its forthcoming initial public offering at $10 to $12 per share, raising up to $54.5 million from the sale of 4.5 million shares, plus about $25 million from a concurrent sale of nearly 2.3 million shares in a private placement with AstraZeneca.